Trial Profile
A Phase 1, Open Label, Multicentre Clinical Trial of SyB C-1101 in Combination With Azacytidine in Patients With Myelodysplastic Syndrome
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Rigosertib (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors SymBio Pharmaceuticals
- 14 Nov 2022 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 30 May 2016 New trial record